Shanghai ZJ Bio Tech Stock Net Income
| 688317 Stock | 19.92 -0.18 -0.90% |
Momentum
Sell Peaked
Oversold | Overbought |
As of the 15th of March 2026, Shanghai trades at 19.92 per share. Key technical indicators include Risk Adjusted Performance of -0.02, variance of 9.81, and Coefficient Of Variation of -3,400. The technical model evaluates historical price movement, trading volume, and volatility patterns to quantify trend strength. Current values are evaluated relative to sector peers and historical ranges.
Shanghai's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time.Shanghai ZJ Bio Tech does not currently have any fundamental trend indicators for analysis. Continue to Equity Screeners for broader equity screening tools.Shanghai |
What if' Analysis
Running a what-if backtest on Shanghai ZJ Bio Tech gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Shanghai's historical reward profile was stable enough to support the current thesis.
| 12/15/2025 |
| 03/15/2026 |
If you invested 0.00 in Shanghai on December 15, 2025 and closed the position today, you would earn 0.00 in total gains. That corresponds to a 0.0% return on investment in Shanghai overall over 90 days. Shanghai is related to or competes with Zhejiang Yayi, Tibet Huayu, Lecron Energy, Xiamen Bank, and Gem Year. Peer context helps frame relative positioning. More
Shanghai Upside and Downside Indicators Overview
Upside and downside indicators for Shanghai summarize momentum balance and potential range context for the stock. They compare current price to recent trend and sentiment readings.
| Information Ratio | -0.02 | |||
| Maximum Drawdown | 28.5 | |||
| Value At Risk | -3.36 | |||
| Potential Upside | 3.0 |
Shanghai Market Risk Indicators Overview
Market risk indicators summarize volatility and return dispersion for Shanghai. The metrics rely on historical prices to describe variability over time.| Risk Adjusted Performance | -0.02 | |||
| Jensen Alpha | -0.1 | |||
| Total Risk Alpha | 0.0745 | |||
| Treynor Ratio | -0.66 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Shanghai's price to converge to an average value over time is called mean reversion.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.02 | |||
| Market Risk Adjusted Performance | -0.65 | |||
| Mean Deviation | 1.57 | |||
| Coefficient Of Variation | -3,400 | |||
| Standard Deviation | 3.13 | |||
| Variance | 9.81 | |||
| Information Ratio | -0.02 | |||
| Jensen Alpha | -0.1 | |||
| Total Risk Alpha | 0.0745 | |||
| Treynor Ratio | -0.66 | |||
| Maximum Drawdown | 28.5 | |||
| Value At Risk | -3.36 | |||
| Potential Upside | 3.0 | |||
| Skewness | 3.82 | |||
| Kurtosis | 26.68 |
Shanghai ZJ Bio Backtested Returns
Shanghai appears to exhibit a low volatility profile over the selected 3 months investment horizon. It records an Efficiency (Sharpe) Ratio of close to zero, indicating risk-adjusted returns over the last 3 months. Volatility modeling revealed twenty-three technical measures impacting risk exposure. Please review metrics such as Coefficient Of Variation of -3,400, risk-adjusted performance of -0.02, and Variance of 9.81 to confirm whether our risk estimates align with your expectations. The company has a beta of 0.15, which means relatively modest fluctuations relative to the market. As returns on the market increase, Shanghai's returns are expected to increase less than the market. However, during a bear market, the loss from holding Shanghai is expected to be smaller as well. Shanghai ZJ Bio currently has a risk of 3.34%. Please check Shanghai ZJ Bio the relationship between the coefficient of variation and jensen alpha.
Auto-correlation | -0.68 |
Very good reverse predictability
The autocorrelation profile for Shanghai ZJ Bio Tech registers very good reverse predictability between the two measured intervals. When lagged price patterns show consistency, they can serve as a partial input for modeling Shanghai ZJ Bio's near-term price behavior. A serial correlation of -0.68 indicates that around 68.0% of current Shanghai price fluctuations can be explained by its historical price movements. Given that Shanghai ZJ Bio Tech has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.68 | |
| Spearman Rank Test | -0.69 | |
| Residual Average | 0.0 | |
| Price Variance | 0.78 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Shanghai ZJ Bio Tech reported net income of -127.46 Million. This is much lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all China stocks is notably higher than that of the company.
Shanghai Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to.Shanghai is currently under evaluation in net income among leading competitors.
Shanghai Fundamentals
| Return On Equity | -0.0401 | |||
| Return On Asset | -0.0464 | |||
| Profit Margin | -1.09 % | |||
| Operating Margin | -0.95 % | |||
| Current Valuation | 1.82 B | |||
| Shares Outstanding | 192.16 M | |||
| Shares Owned By Insiders | 40.67 % | |||
| Shares Owned By Institutions | 6.35 % | |||
| Price To Book | 1.30 X | |||
| Price To Sales | 33.24 X | |||
| Revenue | 178.65 M | |||
| Gross Profit | -80.39 M | |||
| EBITDA | -81.82 M | |||
| Net Income | -127.46 M | |||
| Total Debt | 4.93 M | |||
| Book Value Per Share | 19.12 X | |||
| Cash Flow From Operations | 77.59 M | |||
| Earnings Per Share | -0.76 X | |||
| Number Of Employees | 285 | |||
| Beta | 0.54 | |||
| Market Capitalization | 4.37 B | |||
| Total Asset | 3.79 B | |||
| Retained Earnings | 1.34 B | |||
| Working Capital | 2.79 B | |||
| Net Asset | 3.79 B |
Financial Metrics, Fundamentals & Methodology
Shanghai reports annual revenue of 178.65 M, a profit margin of -109.37%, ROE of -4.01%, an operating margin of -95.28%. Fundamental metrics for Shanghai center around operating performance and capital allocation discipline. The company is currently operating at a loss. Overall market capitalization tier is large-cap. In recent filings, Shanghai posted revenue of 178.65 M, EPS loss of 0.76, negative operating margin of 95.28%.
Unless otherwise specified, data for Shanghai ZJ Bio Tech is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day. Income statement, balance sheet, and cash-flow values follow GAAP or IFRS conventions as reported.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardCurrently Active Assets on Macroaxis
More Resources for Shanghai Stock Analysis
Other Information on Investing in Shanghai Stock
Shanghai financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare Shanghai to other measures in a consistent way.